Retention in a NGO supported antiretroviral program in the Democratic Republic of Congo

PLoS ONE

Volumn 7, Issue 7, 2012, Pages

  Koole, Olivier ^a   Kalenga, Lucien ^b,c   Kiumbu, Modeste ^c   Menten, Joris ^a   Ryder, Robert W ^d   Mukumbi, Henri ^b,c   Colebunders, Robert ^a,e  

^a INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^b AmoCongo ^*  (Congo)

^c School of Public Health   (Congo)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; EFAVIRENZ; LAMIVUDINE; NEVIRAPINE; STAVUDINE; ZIDOVUDINE;

ACCURACY; ADULT; AGED; ARTICLE; BODY WEIGHT; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; CONGO; CONTROLLED STUDY; FEMALE; GEOGRAPHY; HEALTH PROGRAM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; NON GOVERNMENTAL ORGANIZATION; NON PROFIT ORGANIZATION; PATIENT CARE; RETROSPECTIVE STUDY; RISK FACTOR; SCALE UP; SEX DIFFERENCE;

ADOLESCENT; ADULT; AGED; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DEMOCRATIC REPUBLIC OF THE CONGO; FEMALE; GEOGRAPHY; HEALTH SERVICES ACCESSIBILITY; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; ORGANIZATIONS, NONPROFIT; PATIENT COMPLIANCE; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84864009000     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0040971     Document Type: Article

References (28)

1. WHO (2010) Towards universal access: scaling up priority HIV/AIDS interventions in the health sector. Progress report 2010. WHO website. Available:http://whqlibdoc.who.int/publications/2010/9789241500395_eng.pdf. Accessed: 2011 Nov 8.
2. Rosen S, Fox MP, Gill CJ, (2007) Patient retention in antiretroviral therapy programs in sub-Saharan Africa: a systematic review. PLoS Med 4: e298. PLoS Medicine website. Available:http://www.plosmedicine.org/article/info:doi/10.1371/journal.pmed.0040298. Accessed: 2011 Nov 8.
3. Yu JK, Chen SC, Wang KY, Chang CS, Makombe SD, et al. (2007) True outcomes for patients on antiretroviral therapy who are "lost to follow-up" in Malawi. Bull World Health Organ 85: 550-554. WHO website. Available:http://www.who.int/bulletin/volumes/85/7/06-037739.pdf. Accessed: 2011 Nov 8.
4. Bisson GP, Gaolathe T, Gross R, Rollins C, Bellamy S, et al. (2008) Overestimates of survival after HAART: implications for global scale-up efforts. PLoS ONE 3: e1725. PLoS ONE website. Available:http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0001725. Accessed: 2011 Nov 8.
5. Giordano TP, Gifford AL, White AC Jr, Suarez-Almazor ME, Rabeneck L, et al. (2007) Retention in care: a challenge to survival with HIV infection. Clin Infect Dis 44: 1493-1499.
6. WHO (2011) The treatment 2.0 framework for action: catalysing the next phase of treatment, care and support. WHO website. Available:http://whqlibdoc.who.int/publications/2011/9789241501934_eng.pdf. Accessed: 2011 Nov 8.
7. Ministère du plan et Macro International, (2007) Enquête Démographique et de Santé. Ministry of Health- Democratic Republic of Congo website. Available:http://www.minisanterdc.cd/fr/documents/eds.pdf. Accessed: 2011 Nov 8.
8. Tassie JM, Baijal P, Vitoria MA, Alisalad A, Crowley SP, et al. (2010) Trends in retention on antiretroviral therapy in national programs in low-income and middle-income countries. J Acquir Immune Defic Syndr 54: 437-441.
9. Coetzee D, Hildebrand K, Boulle A, Maartens G, Louis F, et al. (2004) Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa. AIDS 18: 887-895.
10. Braitstein P, Brinkhof MW, Dabis F, Schechter M, Boulle A, et al. (2006) Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet 367: 817-824.
11. Ferradini L, Jeannin A, Pinoges L, Izopet J, Odhiambo D, et al. (2006) Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment. Lancet 367: 1335-1342.
12. Cornell M, Grimsrud A, Fairall L, Fox MP, van Cutsem G, et al. (2010) Temporal changes in programme outcomes among adult patients initiating antiretroviral therapy across South Africa, 2002-2007. AIDS 24: 2263-2270.
13. Boulle A, Bock P, Osler M, Cohen K, Channing L, et al. (2008) Antiretroviral therapy and early mortality in South Africa. Bull World Health Organ 86: 678-687. WHO website. Available:http://www.who.int/bulletin/volumes/86/9/07-045294.pdf. Accessed: 2011 Nov 8.
14. Programme National Multisectoriel de Lutte contre le Sida (PNMLS) (2010) Rapport national de suivi de la Déclaration d'engagement (UNGASS). National Multisectoral Programme to control AIDS and STI website. Available:http://www.pnmls.cd/IMG/pdf/Rapport_UNGASS_2010.pdf. Accessed: 2011 Nov 8.
15. MacPherson P, Moshabela M, Martinson N, Pronyk P, (2009) Mortality and loss to follow-up among HAART initiators in rural South Africa. Trans R Soc Trop Med Hyg 103: 588-593.
16. Boyles TH, Wilkinson LS, Leisegang R, Maartens G, (2011) Factors influencing retention in care after starting antiretroviral therapy in a rural South african programme. PLoS ONE 6: e19201. PLoS ONE website. Available:http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0019201. Accessed: 2011 Nov 8.
17. Massaquoi M, Zachariah R, Manzi M, Pasulani O, Misindi D, et al. (2009) Patient retention and attrition on antiretroviral treatment at district level in rural Malawi. Trans R Soc Trop Med Hyg 103: 594-600.
18. Brinkhof MW, Dabis F, Myer L, Bangsberg DR, Boulle A, et al. (2008) Early loss of HIV-infected patients on potent antiretroviral therapy programmes in lower-income countries. Bull World Health Organ 86: 559-567. WHO website. Available:http://www.who.int/bulletin/volumes/86/7/07-044248.pdf. Accessed: 2011 Nov 8.
19. Fox MP, Rosen S, (2010) Patient retention in antiretroviral therapy programs up to three years on treatment in sub-Saharan Africa, 2007-2009: systematic review. Trop Med Int Health 15: 1-15.
20. Calmy A, Pinoges L, Szumilin E, Zachariah R, Ford N, et al. (2006) Generic fixed-dose combination antiretroviral treatment in resource-poor settings: multicentric observational cohort. AIDS 20: 1163-1169.
21. Stringer JS, Zulu I, Levy J, Stringer EM, Mwango A, et al. (2006) Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes. JAMA 296: 782-793.
22. WHO (2010) Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. Revision 2010. WHO website. Available:http://whqlibdoc.who.int/publications/2010/9789241500395_eng.pdf. Accessed: 2011 Nov 8.
23. Mugyenyi P, Walker AS, Hakim J, Munderi P, Gibb DM, et al. (2010) Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial. Lancet 375: 123-131.
24. Charurat M, Oyegunle M, Benjamin R, Habib A, Eze E, et al. (2010) Patient retention and adherence to antiretrovirals in a large antiretroviral therapy program in Nigeria: a longitudinal analysis for risk factors. PLoS ONE 5: e10584. PLoS ONE website. Available:http://www.plosone.org/article/info:doi%2F10.1371%2Fjournal.pone.0010584. Accessed: 2011 Nov 8.
25. May M, Boulle A, Phiri S, Messou E, Myer L, et al. (2010) Prognosis of patients with HIV-1 infection starting antiretroviral therapy in sub-Saharan Africa: a collaborative analysis of scale-up programmes. Lancet 376: 449-457.
26. Forster M, Bailey C, Brinkhof MW, Graber C, Boulle A, et al. (2008) Electronic medical record systems, data quality and loss to follow-up: survey of antiretroviral therapy programmes in resource-limited settings. Bull World Health Organ 86: 939-947. WHO website. Available:http://www.who.int/bulletin/volumes/86/12/07-049908.pdf. Accessed: 2011 Nov 8.
27. MSF Campaign for access to essential medicines, (2009) Punishing success? Early signs of a retreat from commitment to HIV/AIDS care and treatment. MSF Access Campaign website. Available:http://www.msfaccess.org/sites/default/files/MSF_assets/HIV_AIDS/Docs/AIDS_report_PunishingSuccess_ENG_2009.pdf. Accessed: 2011 Nov 8.
28. MSF Campaign for access to essential medicines, (2010) The ten consequences of AIDS treatment delayed, deferred, or denied. MSF Access Campaign website. Available:http://www.msfaccess.org/sites/default/files/MSF_assets/HIV_AIDS/Docs/AIDS_report_10consequences_ENG_2011.pdf. Accessed: 2011 Nov 8.